Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on March 24, 2020, covering events that occurred on March 20, 2020. The filing primarily addresses significant changes to the Company's Board of Directors.
Key Financial Metrics
This filing is a current report regarding corporate governance changes and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
Board of Directors Resignations
- Dr. Brian Bernick (Co-Founder), Mr. John C.K. Milligan, IV (President and Secretary), and Mr. Nicholas Segal resigned from the Board of Directors effective March 20, 2020.
- The resignations were not the result of any disagreement with the Company.
- Mr. Milligan and Dr. Bernick will continue to serve as full-time employees of the Company.
Board of Directors Appointments
- Paul Bisaro and Dr. Gail Naughton were appointed as directors to fill two of the vacancies created by the resignations.
- Both appointees are considered independent under Nasdaq Global Select Market rules.
- They will serve until the 2020 Annual Meeting of Stockholders or until their successors are elected.
- As of March 20, 2020, the Board has 11 authorized directors with one remaining vacancy.
Guidance, Outlook, and Risks
The filing includes a Regulation FD Disclosure referencing a press release dated March 24, 2020, titled "TherapeuticsMD Strengthens Board with Appointment of Industry Leaders." No specific financial guidance, operational outlook, or new risk factors were disclosed in this specific filing. The text notes that the new directors will receive compensation consistent with other non-employee directors as described in the 2019 Definitive Proxy Statement.
Investor Verification Checklist
- Verify the continued employment status and roles of Dr. Bernick and Mr. Milligan following their Board resignations.
- Review the biographies and qualifications of new directors Paul Bisaro and Dr. Gail Naughton.
- Confirm the timeline for filling the remaining single vacancy on the Board of Directors.
- Check the Company's 2019 Definitive Proxy Statement for details on the compensation structure for the new non-employee directors.